Next Article in Journal
Endothelin A Receptors Expressed in Glomeruli of Renal Transplant Patients May Be Associated with Antibody-Mediated Rejection
Next Article in Special Issue
Current Overview on Clinical Management of Chronic Constipation
Previous Article in Journal
The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review
Previous Article in Special Issue
The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients

by
Małgorzata Reszczyńska
1,* and
Radosław Kempiński
2
1
Department of Gastroenterology and Hepatology, Wrocław University Hospital, 50-556 Wrocław, Poland
2
Department of Gastroenterology and Hepatology, Wrocław Medical University, 50-367 Wrocław, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(3), 415; https://doi.org/10.3390/jcm10030415
Submission received: 30 November 2020 / Revised: 16 January 2021 / Accepted: 19 January 2021 / Published: 22 January 2021
(This article belongs to the Special Issue Enteric Nervous System: Neuropathic Gastrointestinal Motility)

Abstract

:
Complications affecting the gastrointestinal tract often occur in the course of diabetes mellitus (DM). The aim of this study was to evaluate enteropathy symptoms and anorectal function using high-resolution anorectal manometry (HRAM). Fifty DM patients and 20 non-DM controls were enrolled into the study. Clinical data and laboratory tests were collected, physical examination and HRAM were performed. Symptoms in the lower gastrointestinal tract were reported by 72% of patients. DM patients with a long disease duration reported anal region discomfort (p = 0.028) and a sensation of incomplete evacuation (p = 0.036) more often than patients with shorter diabetes duration. Overall, DM patients had a lower maximal squeeze pressure (MSP) (p = 0.001) and a higher mean threshold of minimal rectal sensation (p < 0.01) than control subjects. They presented with enhanced features of dyssynergic defection than the control group. MSP and maximal resting pressure (MRP) were significantly lower in the group of long-term diabetes (p = 0.024; p = 0.026 respectively) than in patients with a short-term diabetes. The same observation was noted for patients with enteropathy symptoms that control for MSP (p < 0.01; p < 0.01; p = 0.03) and MRP (p < 0.001; p = 0.0036; p = 0.0046), respectively, for incontinence, constipation, and diarrhea. Symptoms in the lower gastrointestinal tract are often reported by DM patients. All DM patients have impaired function of the external anal sphincter and present enhanced features of dyssynergic defecation and also impaired visceral sensation. Patients with long-standing DM and patients with enteropathy symptoms have severely impaired function of both anal sphincters.

1. Introduction

The prevalence of diabetes mellitus is increasing rapidly due to the worldwide obesity epidemic. Complications occurring over the course of this disease can affect many organs including the gastrointestinal tract [1]. Diabetic enteropathy is a relevant complication, which has a multi-factorial and complex etiology. According to the latest data, many different mechanisms of action lead to the dysfunction of the enteric nervous system, such as microangiopathy, autonomic neuropathy, myopathy, polyneuropathy, and gut microbiome disturbances, which cause dysmotility in the gastrointestinal tract [2,3]. Many factors including hyperglycemia, oxidative stress, and neuro-inflammatory processes reduce levels of nerve growth factors and induce intracellular changes in neurons [2]. Data concerning abnormalities in the upper gastrointestinal tract are published more often than data containing abnormalities of the lower gastrointestinal tract [4]. Complaints such as chronic constipation, anal regional pain, chronic diarrhea, and incontinence are important but often overlooked issues in interdisciplinary medical care of diabetic patients. Anorectal manometry is a routinely used diagnostic method in proctological practice, whereas high-resolution anorectal manometry (HRAM) is a relatively new diagnostic method. It provides detailed data according to anorectal function, which can be abnormal in diabetes mellitus (DM) [5]. According to Eldosky et al., diabetic patients with neuropathy and microangiopathy have severely impaired anorectal function [6].
The aim of this study was to evaluate the prevalence of enteropathy symptoms and to evaluate anorectal function using high-resolution anorectal manometry in all diabetic patients and patients with select enteropathic symptoms (stool incontinence, constipation, and diarrhea) and duration of diabetes.

2. Patients and Methods

The study included 70 individuals: 50 diabetic patients (26 men and 24 women) and 20 non-diabetic (12 men and 8 women) control volunteers. The exclusion criteria for all diabetic patients were as follows: history of neurological conditions (stroke, demyelinating diseases, advanced degenerative disease of the spine), history of spine surgery, an age over 85 years, fasting blood glucose level over 200 mg/dl, and women where the perineal childbirth related injury was greater than the first-degree. The exclusion criteria for the control subjects were: defecation disorders, history of surgical treatment in the minor pelvis and anorectum region, anorectal symptoms, drug intake that could have an impact on the anorectal function, benign prostatic hypertrophy, and women where the perineal injury during childbirth was greater than the first-degree. Control subjects were not diagnosed with any chronic disease. The type of anti- diabetic medications used by patients is illustrated in Table 1 and Table 2. Diabetic patients were divided into subgroups depending on the duration of the disease (less than 10 and over 10 years), symptoms of diabetic autonomic neuropathy (DAN) reported in the questionnaire (with or without DAN symptoms), and glycemic control (based on the reported level of the HbA1c result from the last three months). The diabetic patients were hospitalized in the Department of Angiology, Hypertension and Diabetology, and the Department of Gastroenterology and Hepatology at the University Hospital in Wroclaw. All patients completed the questionnaire, which consisted of demographic and clinical data. Prior to the examination, a test for glucose concentration in capillary blood was collected. Then a digital rectal examination was performed. The evening before the procedure, a preparation with an enema was performed. On the morning of the study patients were fasting and off any medications. The patients underwent the exam in the left lateral position. The anorectal manometry was performed with the ManoScan 360 Sierra Scientific Instruments System. After a digital examination was performed to confirm the absence of stool in the rectum, a high-resolution anorectal manometric catheter with terminal balloon was introduced into the rectum. The examination was performed according to the Rao et al. protocol [7]. The following manometric parameters were evaluated: the maximal anal resting pressure (MRP), the maximal anal squeeze pressure (MSP), cough reflex, the push/strain maneuver, rectal sensation test, the recto-anal inhibitory reflex (RAIR). In addition to the parameters mentioned above, the following were also evaluated: length of the high-pressure zone (HPZ), duration of sustained squeeze, ano-rectal pressure gradient, residual anal pressure (RAP), rectal pressure during the push maneuver, and the rectal compliance. MRP/RAP ratio was calculated.
All patients provided written informed consent to participate in the study, and the study protocol was approved by the human ethics review board of Medical University in Wroclaw (KB-180/2013).

Statistical Analysis

Numerical data are presented as mean ± standard deviation, median, minimal, and maximal value. The differences between percentages of certain characteristic in each group were determined by chi-squared test. For the differences between two groups, U Mann-Whitney test was used. p-value < 0.05 was considered statistically significant.

3. Results

At least one chronic symptom was reported by 39 diabetic patients (78%). Symptoms from the lower part of the gastrointestinal tract were reported by 36 (72%) of patients. In Table 3, the frequency of gastrointestinal symptoms in diabetic patients with gender distribution is shown. The most often reported symptom was abdominal bloating (64%). With a similar frequency of patients reporting abdominal pain and a sensation of incomplete evacuation (60% and 62%, respectively). The most often reported symptom from the lower gastrointestinal tract was incontinence of the stool and/or gas and the sensation of urgent defecation (N = 22; 44% and N = 21; 42%, respectively). Incontinence with liquid stool was reported by 13 patients (26%). The least reported symptom was alternating diarrhea and constipation (N = 6; 12%). Chronic constipation and diarrhea were diagnosed with the same frequency (N = 15; 30% each group). Anal region discomfort was present in 14 patients (28%). Some symptoms were more often reported by women: incontinence of stool and/or gas (p = 0.011), anal region discomfort (p = 0.039), as well as a sensation of incomplete evacuation (p = 0.016).
Diabetic patients with a disease duration of over 10 years reported anal region discomfort 37% (p = 0.028) and a sensation of incomplete evacuation 40% (p = 0.036) more often than patients with a shorter duration of diabetes. There were 31 patients with DAN symptoms. Table 4 illustrates the frequency of diabetic autonomic neuropathy symptoms reported by patients in the questionnaire. Patients with symptoms of autonomic neuropathy more often reported abdominal pain 74% (p = 0.009) and a sensation of incomplete evacuation 74% (p = 0.023) than patients without symptoms. Glycemic control did not influence the frequency of symptoms (Table 5).
Manometric parameters and selected functional tests for all diabetic patients are shown in Table 6 and Table 7. Overall diabetic patients had a lower MSP (p = 0.001) and a higher mean threshold of minimal rectal sensation (p < 0.01) than the control subjects. In the group of diabetic patients, 8 patients failed to exhibit RAIR, whereas none of the controls did. Evaluation of the push/strain maneuver revealed that diabetic patients had a lower recto-anal pressure differential (p = 0.012) and a higher residual anal pressure (RAP) (p = 0.044). The differences in MRP/RAP between the two groups were statistically significant and were compatible with the other parameters used to assess the push/strain maneuver.
Evaluation of anorectal function in patients with enteropathy symptoms revealed many differences, which are presented in Table 8 and Table 9. MRP and MSP were significantly lower in all groups of diabetic patients with selected enteropathy symptoms than in the control group p < 0.01; p < 0.01; p = 0.003, respectively, for incontinence, constipation, and diarrhea for MSP and p = 0.003; p = 0.036; p = 0.046, respectively, for incontinence, constipation, and diarrhea for MRP.
Patients with diabetes and chronic constipation had a lower anorectal pressure gradient and MRP/RAP compared to the control subjects p < 0.03 and p < 0.04, respectively. Whereas patients with chronic diarrhea had only MRP/RAP lower p < 0.04 in all the parameters used to evaluate the push/strain maneuver. Significant differences were found in the first sensation threshold between the symptomatic patients and the control group for incontinence, constipation, and diarrhea (p < 0.01; p < 0.01; p < 0.02 respectively). Patients with diabetes and chronic constipation had a higher mean threshold sense of urge to defecate than control subjects p < 0.05. Diabetic patients with incontinence and diabetic patients with chronic diarrhea had lower volumes of RAIR first time detection than the control subjects (p < 0.01; p < 0.04, respectively). RAIR was statistically more significant and frequently absent in the group of diabetic patients with incontinence than in the control subjects (p < 0.003).
Evaluation of HRAM variables depending on the duration of diabetes revealed that MRP and MSP was significantly lower in the group of long-standing diabetes (p = 0.024; p = 0.026, respectively) than in the group of shorter diabetes duration (less than 10 years) (Table 10). The MRP and MSP values of patients with shorter duration of diabetes were comparable to the results of the control subjects.

4. Discussion

Seventy-eight percent of diabetic patients reported chronic symptoms from the gastrointestinal tract, which was shown in previous studies [8,9,10]. Symptoms from the lower gastrointestinal tract were reported by 72% of patients. Higher frequency of symptoms from the lower gastrointestinal tract were also observed by Jeong Hawn et al. [10]. The sensation of incomplete defecation was present in 62% of patients, which is more often than in previous studies, 54.3% [11] and 40.5% [9]. The correlation of incomplete evacuation sensation in diabetes was also proved by the study of Jorge et al. [11] and Ihana-Sugiyama et al. [12]. In Jorge et al.’s study, patients with severe incomplete defecation sensation had lower resting anal pressure. In the presented study this symptom was significantly more often observed in the group of long-standing diabetes with the symptoms of DAN. Anal region discomfort was observed in 28% of patients and was significantly more often reported in women and patients with long-standing diabetes. The symptom was more often reported than in the results presented in a single study by Jeong Hawn et al. [10]. The presented correlation with long standing-diabetes is a new observation and needs further research. It can be related to polyneuropathy and DAN, which are more often observed in long-standing diabetes [6,13]. Considering that pudendal nerve fibers innervate the anal canal wall and the skin in the anal region [14], anal region discomfort could be additional evidence of polyneuropathy. Bytzer et al. [15] and Jung-Hwan O et al. [9] in their studies presented equal symptom rates in men and women with no correlation between gender and symptom frequency, respectively. In the presented study, anal region discomfort, sensation of incomplete evacuation, and incontinence were significantly more often reported by women. Pintor et al. presented the correlation between the incontinence and neuropathy [16]. In population-based studies, the appearance of incontinence was not related to gender [17]. In women, except in cases of mechanical injury to the pelvic floor muscles, neuropathy of the pudendal nerves could be observed after childbirth, and could lead to incontinence even many years after labor. Therefore in the authors opinion, diabetes can also be an independent additional risk factor for incontinence in women. Symptoms of diabetic enteropathy such as constipation, diarrhea, and incontinence of the stool and/or gas were reported in 30%, 30%, and 44% of patients, respectively. Twenty-six percent of patients presented incontinence of liquid stool, Epanomeritakis et al. [13] reported frequency of 31.5%, whereas Deen et al. 40% [18] of stool incontinence, which corresponded to the presented results. According to numerous authors, constipation is the most common symptom of enteropathy, present in up to 60% of cases [19,20,21]. The mechanism of constipation is complex, including slow bowel transit and/or dyssynergic defecation. Correlation between the slow transit and the presence of neuropathy was proven [22,23]. Slow bowel transit was also observed among patients with diabetes in the Hye-Kyung J et al. study [24]. ICC (Interstitial cell of Cajal) acts as the neurotransmitters between the enteric nervous system (ENS) and the smooth muscles. The lower amount of ICC and ENS cells in diabetic patients, probably leads to the disturbance in motor function of the gastrointestinal tract including bowels [2,3,25,26,27]. Additionally, myopathy is another etiological factor for enteropathy [3]. The glycemic control (based on the level of the HbA1c) did not influence the frequency of symptoms from the lower gastrointestinal tract, which corresponded with the majority of previous reports. In contrast, Khoshbaten et al. presented a correlation between unbalanced diabetes and higher frequency of constipation and diarrhea (it was based on the questionnaire rather than the HbA1c laboratory results) [28]. There are many positive data considering the correlation between higher HbA1c values and higher frequency of upper gastrointestinal tract symptoms [10,15,29,30,31]. Why a similar correlation is not observed in accordance to the symptoms of lower gastrointestinal tract still needs to be studied. Zhang et al. is presenting the theory about the adverse effect of hyperglycemia on the vagal nerve which leads to the delaying of gastric emptying or other mechanism via the central nervous system [32].
Evaluation of the anorectal function with the use of high-resolution anorectal manometry revealed that squeeze activity of the anal sphincters was impaired in diabetic patients in comparison to the control subjects. The MSP was lower in all diabetic patients, whereas the MRP and MSP were lower in all patients with enteropathy symptoms and patients with long-standing diabetes, as was the MSP/MRP ratio. The results corresponded to some others studies in which both MRP and MSP were lower in diabetic patients [6,13]. In contrast, the results of Deen et al. reported no significant differences in pressure within the anal canal [18], even in the studied group there were patients with incontinence who exhibited incorrect RAIR reflex, suggesting the possibility of neuropathy. This proved the complexity of pathophysiological processes in diabetic complications. Epanomeritakis et al. concluded that there is an increased incidence of incontinence in patients with long standing diabetes [13] (in the presented study, the frequency was also higher, but the result was not statistically significant). This corresponds with the observation of lower squeeze pressure and dysfunction of EAS (external anal sphincter). Lower squeeze activity in the anal canal may be related to motor peripheral neuropathy of pudendal nerves and S3-S4 nerves roots (EAS and pubo-rectalis muscle innervation) [14,33], which is not common in the early stages of diabetes [34] or neuropathy of autonomic nerves, which is responsible for internal anal sphincter (IAS) innervations. The subclinical autonomic neuropathy may appear early in the first year after diagnosis of diabetes type 2 or two years after type 1, whereas the first symptoms may be detected many years later [1]. It was demonstrated that there are special Cajal cells (ICC-M) in IAS in monkeys, which can act as independent starters, not only as transmitters of nervous impulse, as previously thought [35]. The number of ICC cells in diabetic patients with gastrointestinal symptoms decreases, which can be one of the reasons for lower IAS tone [25]. An additional mechanism can be myopathy [2,3] or other mechanisms that are still being studied (as the role of the micro-RNA and its influence on IAS tone) [36]. All diabetic patients had impaired visceral sensation manifested by higher threshold value of first sensation and higher threshold value of urge to defecate noted only in patients with chronic constipation. These results are consistent with previous reports presenting higher threshold values for rectal sensations [6,37]. Patients with longstanding diabetes had much higher values of first sensation threshold than patients with a short history of diabetes but the result was not statistically significant. Probably, the dysfunction of the autonomic regulation of rectum sensation results in hyposensitivity of the rectum. However, Epanomeritakis et al. presented lower threshold values in diabetic patients [13]. Rogers et al. presented no differences according to the visceral sensation test between diabetic patients with peripheral neuropathy, healthy subjects, and patients with idiopathic incontinence [38]. Studies mentioned above present a divergence between the results of the nature of impaired visceral sensation in diabetic patients. The study of Softelan et al. provided evidence of the pathological changes in both autonomic and peripheral nervous systems in diabetic patients [4]. The rectum has autonomic innervations from sympathetic and parasympathetic fibers. Rectal sensation is mediated by parasympathetic fibers that pass from S2 to S4 and impaired rectal sensation in diabetic patients could be additional evidence of DAN [39]. In patients with diabetes and liquid stool incontinence and/or diarrhea, the lower volume of balloon distention was needed for IAS relaxation (RAIR reflex). The absence of RAIR reflex was more often noted in patients with incontinence. Deen et al. also presented impaired RAIR reflex in patients with incontinence [18]. Probably, the observed impaired RAIR reflex is the result of many complex mechanisms such as neuropathy of the rectal nervous plexus, dysfunction of nitrergic neurons in the rectal wall [18], and reduced production of nitric-oxide, a neurotransmitter responsible for smooth muscles relaxation [25,40]. One of the parameters used for evaluation of dyssynergic defecation is the recto-anal pressure gradient. In the presented study, this gradient was significantly lower in all diabetic patients and significantly lower in patients with constipation than in control subjects, which presented enhanced features of dyssynergic defecation and suggest its appearance more often in diabetic patients. Maleki et al., in a small study (only 10 patients) evaluating the dyssynergic defecation in patients with constipation, reported that it was more often observed in patients with constipation and diabetes [41]. These results are in agreement with the presented study and need further research.

Recommendations for Clinical Practice

The most important issue for the control of the symptoms in the lower gastrointestinal tract in diabetic patients is blood glucose level control. All diabetic patients should be advised lifestyle changes such as extensive physical activity (aerobic and resistance training) at least twice a week, 1000 steps extra a day. It can improve insulin action, glycemic control, lipid levels, and blood pressure. A proper diet is also an important issue [42]. All patients with a slow bowel transit mechanism of constipation should have adequate water and soluble fiber intake (20–30 g per day) [21,43]. Patients with diagnosed constipation related to the dyssynergic defecation are candidates for biofeedback therapy. Following the Rome IV Diagnostic Criteria for Irritable Bowel Syndrome (IBS), methyl cellulose therapy is recommended in chronic constipation. Next to consider are osmotic laxatives which can also be used for patients with dyssynergic defecation. In this group, stimulant laxatives are not recommended as they can worsen the symptoms. Considering impairing bowel movements in diabetes patients using prokinetic drugs such as cisapride can be used as first line therapy [21,43]. Mosapride was effective for severe constipation cases in DM patients both in terms of bowel movement improvement and diabetic control [44]. The diarrhea treatment in DM patients is mostly conservative. Again it should be highlighted that good diabetic control is the most important issue. A diet with low fiber intake and frequent small meal portions are important. Loperamide therapy delays bowel movements and increases the tension of the internal anal sphincter which can be useful also for patients with stool incontinence (2–4 mg 30 min. before the meal—max 16 mg/24 h). In cases of sever diabetic diarrhea, somatostatin analogue therapy can be considered [43,45]. In stool incontinence cases, the alternative treatment can be amitriptyline, which can also reduce urgency to defecate [43,46]. Patients with diabetic stool incontinence, without mechanical injury of the sphincters, can be treated with biofeedback therapy [47]. There are also more advanced methods of treatment (transrectal sphincter stimulation, surgical methods) that can be considered [46].

5. Conclusions

In conclusion, symptoms of the lower gastrointestinal tract are often reported by diabetic patients as there is a correlation with impaired anorectal function. In the author’s opinion, diabetes can be an independent and additional risk factor for incontinence in women. Patients with long-standing diabetes presented with lower resting and squeeze anal tone and presented in clinical settings with symptoms such as anal region discomfort and incomplete evacuation sensation. All diabetic patients presented enhanced features of dyssynergic defecation. These symptoms can negatively impact an individual’s quality of life and need to be taken into consideration in diabetic care. The highlight of this study is displaying the relationship between the duration of diabetes and its impact on anorectal function and related symptoms. More advanced supervision and close cooperation between diabetics and gastroenterology specialists should be implemented to improve patient care.

Author Contributions

Conceptualization, M.R.; methodology, M.R.; software, M.R., R.K.; validation, M.R., R.K.; formal analysis, M.R.; investigation, M.R.; resources, M.R.; data curation, M.R., R.K.; writing—original draft preparation, M.R.; writing—review and editing, M.R., R.K.; visualization, M.R., R.K.; supervision, M.R., R.K.; project administration, M.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. 100% discount of APC was provided by Editor.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee Wrocław Medical University (KB-180/2013).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are not publicly available but are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest

Abbreviations

RAPresidual anal pressure
DANdiabetic autonomic neuropathy
EASexternal anal sphincter
HPZhigh pressure zone
HRAMhigh resolution anorectal manometry
IASinternal anal sphincter
ICCInterstitial Cajal cells
MRPmaximal resting pressure
MSPmaximal squeeze pressure
RAIRrecto-anal inhibitor reflex

References

  1. World Health Organisation. Global Report on Diabetes; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
  2. Yarandi, S.S.; Srinivasan, S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: Current status and future directions. Neurogastroenterol. Motil. 2014, 26, 611–624. [Google Scholar] [CrossRef]
  3. Gregersen, H.; Liao, D.; Drewes, A.M.; Drewes, A.M.; Zhao, J. Ravages of Diabetes on Gastrointestinal Sensory-motor Function: Implications for Pathophysiology and Treatment. Curr. Gastroenterol. Rep. 2016, 18, 6. [Google Scholar] [CrossRef] [PubMed]
  4. Softeland, E.; Brock Ch Frokjer, J.B.; Simer, M.; Drewes, A.M.; Dimceveski, G. Rectal sensitivity in diabetes patients with symtoms of gastroparesis. J. Diabetes Res. 2014, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Lee, T.H.; Bharucha, A.E. How to perform and interpret a high-resolution anorectal manometry test. J. Neurogastroenetrol. Motil. 2016, 22, 46–59. [Google Scholar] [CrossRef] [PubMed]
  6. Eldesoky, A.; Bahgat, M.; El-Sherrif, M.; El-Gamal, S.; Taha, K. Anorectal dysfunction in diabetic autonomic neuropathy and microangiopathy. Arab. J. Gastroenterol. 2010, 11, 79–82. [Google Scholar] [CrossRef]
  7. Rao, S.S.; Azpiroz, F.; Diamant, N.; Enck, P.; Tougas, G.; Wald, A. Minimum standards of anorectal manometry. Neurogastroenterol. Motil. 2002, 14, 553–559. [Google Scholar] [CrossRef] [Green Version]
  8. Folowaczny, C.; Riepl, R.; Tschop, M.; Landgraf, R. Gastrointestinal involvement in patients with diabetes mellitus: Part I. Epidemiology, pathophysiology, clinical findings. Gastroenterologie 1999, 37, 803–815. [Google Scholar]
  9. Oh, J.H.; Choi, M.G.; Kang, M.I.; Lee, K.M.; Kim, J.I.; Kim, B.W.; Lee, D.S.; Kim, S.S.; Choi, H.; Han, S.W.; et al. The prevalence of Gastrointestinal Symptoms in patients with Non-Insulin Dependent Diabetes Mellitus. Korean J. Intern. Med. 2009, 24, 309–317. [Google Scholar] [CrossRef]
  10. Kim, J.H.; Park, H.S.; Ko, S.Y.; Hong, S.N.; Sung, I.K.; Shim, C.S.; Song, K.H.; Kim, D.L.; Kim, S.K.; Oh, J. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes. World J. Gastroenterol. 2010, 16, 1782–1787. [Google Scholar] [CrossRef]
  11. Jorge, J.X.; Borges, C.I.C.; Panão, E.A.; Delgado, F.J.; Simões, M.A.; Coelho, Á.C.; Silva, A.L.; Almeida, C.C. Recto-anal manometric characteristic of type 2 diabetes patients who have sensation of incomplete defecation. J. Diabetes Its Complicat. 2013, 27, 167–170. [Google Scholar] [CrossRef]
  12. Ihana-Sugiyama, N.; Nagata, N.; Yamamoto-Honda, R.; Izawa, E.; Kajio, H.; Shimbo, T.; Kakei, M.; Uemura, N.; Akiyama, J.; Noda, M. Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. World J. Gastroenterol. 2016, 21, 3252–3260. [Google Scholar] [CrossRef] [PubMed]
  13. Epanomeritakis, E.; Koutsoumbi, P.; Tsiaoussis, I.; Ganotakis, E.; Vlata, M.; Vassilakis, J.S.; Xynos, E. Impairment of anorectal function in diabetes parallels duration of disease. Dis. Colon. 1999, 42, 1394–1400. [Google Scholar] [CrossRef] [PubMed]
  14. Baharucha, A.E. Pelvic floor anatomy and function. Neurogastroenetrol. Motil. 2006, 18, 507–519. [Google Scholar] [CrossRef] [PubMed]
  15. Bytzer, P.; Talley, N.J.; Lemon, M.; Young, L.J.; Jones, M.P.; Horowitz, M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15,000 adults. Arch. Intern. Med. 2001, 161, 1989–1996. [Google Scholar] [CrossRef] [Green Version]
  16. Pintor, M.P.; Zara, G.P.; Valletto, E.; Demattei, M.; Carta, Q.; Masenti, E. Pudendal neuropathy in diabetic patients with fecal incontinence. J. Colorect. Dis. 1994, 9, 105–109. [Google Scholar] [CrossRef]
  17. Bharucha, A.E.; Dunivan, G.C.; Goode, P.S.; Lukacz, E.S.; Markland, A.D.; Matthews, C.A.; Mott, L.; Rogers, R.G.; Zinsmeister, A.R.; Whitehead, W.E.; et al. Epidemiology, pathophysiology and classification of fecal incontinence: State of Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Am. J. Gastroenterol. 2015, 110, 127–136. [Google Scholar] [CrossRef] [Green Version]
  18. Deen, K.I.; Permaratna, R.; Fomseka, M.M.D.; De Silva, H.J. The recto-anal inhibitor reflex: Abnormal response in diabetics suggests an intrinsic neuropathy. J. Gastroenterol. Hepatol. 1998, 13, 1107–1110. [Google Scholar] [CrossRef]
  19. Krishnan, B.; Babu, S.; Walker, J.; Walker, A.B.; Pappachan, J.M. Gastrointestinal complications of diabetes mellitus. World J. Diabetes 2013, 4, 51–63. [Google Scholar] [CrossRef]
  20. Shakil, A.; Church, R.J.; Rao, S.S. Gastrointestinal complications of diabetes. Am. Fam. Physician 2008, 15, 1697–1702. [Google Scholar]
  21. Bekele, G.; Kabadi, U.M. Gastrointestinal manifestation of diabetes mellitus. Int. J. Diab. Dev. Ctries. 1996, 16, 54–58. [Google Scholar]
  22. Werth, B.; Meyer-Wyss, B.; A Spinas, G.; Drewe, J.; Beglinger, C. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with or without cardiovascular signs of autonomic neuropathy. Gut 1992, 33, 1199–1203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Kawagishi, T.; Nishizawa, Y.; Okuno, Y.; Sekiya, K. Segmental gut transit in diabetes mellitus: Effect of cisapride. Diabetes Res. Clin. Pract. 1992, 17, 137–144. [Google Scholar] [CrossRef]
  24. Hye-Kyung, J.; Doe-Young, K.; Il-Hwan, M.; Young-Sun, H. Colonic Transit time in diabetic patients- comparison with healthy subjects and the effect of autonomic neuropathy. Yonsei Med. J. 2003, 44, 265–272. [Google Scholar]
  25. Ordög, T.; Hayashi, Y.; Gibbons, S.J. Cellular pathogenesis of diabetic gastroenteropathy. Minerva Gastroenterol. Dietol. 2009, 55, 315–343. [Google Scholar]
  26. He, C.L.; Soffer, E.E.; Ferris, C.D. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001, 121, 427–434. [Google Scholar] [CrossRef] [PubMed]
  27. Nakahara, M.; Isozaki, K.; Hirota, S. Deficiency of KIT-positive cells in the colon of patients with diabetes mellitus. J. Gastron. Hepatol. 2002, 17, 666–670. [Google Scholar] [CrossRef]
  28. Khoshbaten, M.; Madad, L.; Baladast, M.; Mohammad, M.; Aliasgarzadeh, A. Gastrointestinal signs and symptoms among persons with diabetes mellitus. Gastroenterol. Hepatol. Bed Bench 2011, 4, 219–223. [Google Scholar]
  29. Bytzer, P.; Talley, N.; Hammer, J.; Young, L.J.; Jones, M.; Horowitz, M. GI symptoms in diabetes mellitus are associated with poor glycemic control and diabetic complications. Am. J. Gastroenterol. 2002, 97, 604–611. [Google Scholar] [CrossRef]
  30. Abid, S.; Jafri, W.; Rizvi, A.; Jahan, F.; Rabbani, F.; Islam, N.; Khan, M.K.; Masood, R. Poor glycemic control is the major factor associated with increased frequency of gastrointestinal symptoms in patients with diabetes mellitus. J. Pak. Med. Assoc. 2007, 57, 345–349. [Google Scholar]
  31. Schvarcz, E.; Palmer, M.; Ingberg, C.M.; Aman, J.; Berne, C. Increased prevalence in upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet. Med. 1995, 13, 478–481. [Google Scholar] [CrossRef]
  32. Zhang, Q.; Horowitz, M.; Rigda, R.; Rayner, C.; Worynski, A.; Holloway, R.H. Effects og hyperglycemia on triggering of transient lower esophageal sphincter relaxation. Am J. Physiol. Gastrointest. Liver Physiol. 2004, 286, 797–803. [Google Scholar] [CrossRef] [PubMed]
  33. Dziki, A. Anatomia i fizjologia dolnego odcinka przewodu pokarmowego. In Proktologia; Bielecki, K., Dziki, A., Eds.; Wydawnictwo Lekarskie PZWL: Warszawa, Poland, 2000; pp. 17–43. [Google Scholar]
  34. Jameson, J.S.; Scott, A.N. Medical causes of faecal incontinence. Eur. J. Gastroenetrol. Hepatol. 1997, 9, 428–430. [Google Scholar] [CrossRef] [PubMed]
  35. Cobine, C.A.; Henning, G.W.; Bayguinov, Y.R.; Hatton, W.J.; Ward, S.M.; Keef, K.D. Interstitial cells of Cajal in the cynomolgus monkey rectoanal region and their relationship to sympathetic and nitrergic nerves. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G643–S656. [Google Scholar] [CrossRef] [Green Version]
  36. Singh, J.; Mohanty, I.; Addya, S.; Philllips, B.; Yong, H.M.; An, S.S.; Penn, R.B.; Rattan, S. Role of differentially expressed microRNA-139-5p in the regulation of phenotypic internal anal sphincter smooth muscle tone. Sci. Rep. 2017, 7, 1477. [Google Scholar] [CrossRef]
  37. Wald, A.; Tunuguntla, A.K. Anorectal sensorimotor dysfunction in fecal incontinence and diabetes mellitus. Modification with biofeedback therapy. N. Engl. J. Med. 1984, 310, 1282–1287. [Google Scholar] [CrossRef] [PubMed]
  38. Rogers, J.; Levy, M.D.; Henry, M.M.; Misiewicz, J.J. Pelvic floor neuropathy: A comparative study of diabetes mellitus and idiopathic fecal incontinence. Gut 1988, 29, 756–761. [Google Scholar] [CrossRef]
  39. Wang, Y.H.; Wiseman, J. Anatomy, Abdomen and Pelvis, Rectum; StatPearls Publishing: Treasure Island, FL, USA, 2020. [Google Scholar]
  40. Vinik, A.I.; Maser, R.E.; Mitchell, B.D.; Freeman, R. Diabetic autonomic neuropathy. Diabetes Care 2003, 26, 1553–1579. [Google Scholar] [CrossRef] [Green Version]
  41. Maleki, D.; Camilleri, M.; Burton, D.D.; Rath-Harvey, D.M.; Oenning, L.; Pemberton, J.H.; Low, P.A. Pilot study of pathophysiology of constipation among community diabetes. Dig. Dis. Sci. 1998, 43, 2373–2378. [Google Scholar] [CrossRef]
  42. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed incollaboration with the EASD. The Task Force for diabetes, pre-diabetes, and cardiovasculardiseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2020, 41, 255–323.
  43. Horowitz, M.; Samsom, M. (Eds.) Gastrointestinal Function in Diabetes Mellitus; John Wiley & Sons: Hoboken, NJ, USA, 2004. [Google Scholar]
  44. Ueno, N.; Inui, A.; Satoh, Y. The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res. Clin. Pract. 2010, 87, 27–32. [Google Scholar] [CrossRef]
  45. Maisey, A. A Practical Approach to Gastrointestinal Complications of Diabetes. Diabetes Ther. 2016, 7, 379–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Bharucha, A.E. Management of fecal incontinence. Gastroenterol. Hepatol. 2008, 11, 807–817. [Google Scholar]
  47. Heymann, S.; Scarlett, Y.; Jones, K.; Ringel, Y.; Drossman, D.; Whitehead, W. AGA Institute abstract. Randomized controlled trial shows biofeedback to be superior to alternative treatments for patients with fecal incontinence. Dis. Colon. Rectum. 2009, 52, 1730–1737. [Google Scholar] [CrossRef] [PubMed]
Table 1. Type of anti-diabetic medications.
Table 1. Type of anti-diabetic medications.
Diabetes MedicationsPatients%
Insulin1224
Diabetic oral agents2244
Mix treatment (both oral agents and insulin)1632
Table 2. Diabetic oral agents.
Table 2. Diabetic oral agents.
AgentPatients%
Metformin3162
Sulfonylureas1938
Acarbose36
Incretin-based therapy612
Thiazolidinedione therapy12
Table 3. The frequency of gastrointestinal symptoms in diabetic patients with gender distribution.
Table 3. The frequency of gastrointestinal symptoms in diabetic patients with gender distribution.
VariablesSexDM Patients
(N = 50)
p
Men
(N = 26)
Women
(N = 24)
N%N%N%
Abdominal painnot present1246.2%833.3%2040.0%0.355
present1453.8%1666.7%3060.0%
Abdominal bloatingnot present830.8%1041.7%1836.0%0.423
present1869.2%1458.3%3264.0%
Anal region discomfortnot present2284.6%1458.3%3672.0%0.039
present415.4%1041.7%1428.0%
Diarrheanot present1973.1%1666.7%3570.0%0.621
present726.9%833.3%1530.0%
Constipationnot present2180.8%1458.3%3570.0%0.084
present519.2%1041.7%1530.0%
Alternating diarrhea and constipationnot present2388.5%2187.5%4488.0%0.917
present311.5%312.5%612.0%
Sensation of incomplete evacuationnot present1453.8%520.8%1938.0%0.016
present1246.2%1979.2%3162.0%
Urgent defecationnot present1661.5%1354.2%2958.0%0.598
present1038.5%1145.8%2142.0%
Incontinence of the stool and/or gasnot present1973.1%937.5%2856.0%0.011
present726.9%1562.5%2244.0%
Table 4. Diabetic autonomic neuropathy symptoms.
Table 4. Diabetic autonomic neuropathy symptoms.
SymptomPatients%
Faint714
Tachycardia at rest1632
Lower libido, erection dysfunction1765
Increased sweating2040
Urinary problems1530
The lack of typical hypoglycemia symptoms1122
Table 5. The frequency of gastrointestinal symptoms in diabetic patients depending on glycemic control.
Table 5. The frequency of gastrointestinal symptoms in diabetic patients depending on glycemic control.
VariablesGlycemic Controlp
Good (n = 25)Bad (n = 25)
n%n%
Abdominal painnot present936.0%1144.0%0.564
present1664.0%1456.0%
Abdominal bloatingnot present1040.0%832.0%0.556
present1560.0%1768.0%
Anal region discomfortnot present1664.0%2080.0%0.208
present936.0%520.0%
Diarrheanot present1976.0%1664.0%0.355
present624.0%936.0%
Constipationnot present1664.0%1976.0%0.355
present936.0%624.0%
Alternating diarrhea and constipationnot present2184.0%2392.0%0.384
present416.0%28.0%
Incontinence of the stool not present1768.0%2080.0%0.333
present832.0%520.0%
Sensation of incomplete evacuationnot present1040.0%936.0%0.771
present1560.0%1664.0%
Urgent defecationnot present1456.0%1560.0%0.774
present1144.0%1040.0%
Incontinence of gasnot present1560.0%1664.0%0.771
present1040.0%936.0%
Good glycemic control for DM type 1—HgA1C ≤ 6.5 and for DM type 2—HgA1C ≤ 7.
Table 6. Manometric parameters in diabetic patients and controls.
Table 6. Manometric parameters in diabetic patients and controls.
VariablesDM (N = 50)Control (N = 20)U Mann-Whitney Test
XSDMMinMaxXSDMMinMaxp
MRP (mmHg)84.8724.3984.8518.00123.9094.0712.9695.5070.00115.000.133
MSP (mmHg)164.8871.95158.2520.10388.10230.0459.79245.15137.60326.300.001
MSP/MRP1.960.741.870.924.442.490.792.511.484.660.008
HPZ (cm)3.560.773.701.604.803.440.643.501.804.300.362
Duration of sustained squeeze (s)14.825.6216.802.5020.1015.074.6016.204.0020.100.814
RAP (mmHg)75.2527.8072.1023.40133.1061.3822.7352.7033.30121.000.044
Recto-anal pressure differential−26.5829.91−22.95−99.4060.70−5.5229.56−0.90−62.9040.800.012
The rectal pressure during the push maneuver (mmHg)47.5126.4649.60−18.5096.4055.9026.4660.4511.40109.200.210
RAIR (mL)44.6037.1040.000.00170.0052.5014.1050.0030.0070.000.053
First sensation (mL)47.0025.5040.0020.00140.0028.503.6630.0020.0030.00<0.01
Defecation threshold (mL)85.8038.2370.0030.00200.0074.009.4075.0060.0090.000.578
Minimum compliance−0.111.800.28−11.100.670.370.270.330.131.390.292
Maximum compliance4.183.543.471.4425.604.314.402.931.3519.500.304
MRP/RAP1.220.471.130.543.041.690.561.760.953.060.00
MRP—maximal resting pressure; MSP—maximal squeeze pressure; HPZ—high-pressure zone; RAP—residual anal pressure; RAIR—recto-anal inhibitory reflex; X—mean; SD—standard deviation; M—median Min—minimal; Max—maximal; p < 0.05.
Table 7. Functional manometric tests in diabetic patients and controls.
Table 7. Functional manometric tests in diabetic patients and controls.
VariablesDMControlp
N%N%
RAIRpresent816.0%00.0%0.057
not present4284.0%20100.0%
Cough reflexcorrect4896.0%20100.0%0.364
incorrect24.0%00.0%
Maximum tolerated volume (MTV)<100 mL510.0%00.0%0.056
100–200 mL1020.0%945.0%
>200 mL3570.0%1155.0%
Table 8. Manometric parameters in diabetic patients with selected enteropathy symptom.
Table 8. Manometric parameters in diabetic patients with selected enteropathy symptom.
VariablesIncontinence (N = 13)Constipation (N = 15)Diarrhea (N = 15)Control (N = 20)
XSDMMinMaxXSDMMinMaxXSDMMinMaxXSDMMinMax
MRP (mmHg)69.032.1579c418.0099.0081.8917.6982.9044.50115.7078.1426.4980.0018.00118.9094.0712.9695.5070.00115.00
MSP (mmHg)120.5072.57104.320.10299.7140.647.84132.365.40229.80148.9677.10143.6020.10299.70230.0459.79245.2137.60326.30
MSP/MRP1.790.851.591.023.501.730.491.770.922.671.910.951.621.024.442.490.792.511.484.66
RAP (mmHg)56.3216.8558.5027.3078.9071.3530.7068.1023.40133.1065.0926.9059.1027.30121.7061.3822.7352.7033.30121.00
RAPD−9.2419.3−12.6−48.621.7−30.626.7−22.9−74.44.3−20.629.0−14.7−84.821.7−5.5229.6−0.90−62.940.8
RPPM (mmHg)4722.250.012.890.940.7029.1045.70−18.585.3044.3223.8636.9012.8090.9055.9026.4660.4511.40109.20
RAIR (mL)31.5430.2330.000.0080.0051.3340.6850.000.00130.0036.6730.3940.000.00100.0052.5014.1050.0030.0070.00
FS (mL)50.0029.7240.0020.00140.058.6737.2050.0020.00140.0038.0013.2040.0020.0060.0028.503.6630.0020.0030.00
DF (mL)76.9238.8170.0040.00200.0106.047.4890.0050.00200.0066.6716.337030.00100749.4075.060.090.0
MRP/RAP1.250.491.220.542.061.350.651.140.603.041.280.461.160.662.061.690.561.760.953.06
X—mean; SD—standard deviation. M—median Min—minimal. Max—maximal; p < 0.05; RAPD—recto-anal pressure differential; RPPM—the rectal pressure during the push maneuver; FS—first sensation; DF—defecation threshold.
Table 9. U Mann—Whitney test results for diabetic enteropathy symptoms vs. control subjects.
Table 9. U Mann—Whitney test results for diabetic enteropathy symptoms vs. control subjects.
VariablesIncontinence
vs. Control
Constipation
vs. Control
Diarrhea
vs. Control
ppp
MRP (mmHg)0.0030.0360.046
MSP (mmHg)<0.01<0.010.003
MSP/MRP0.0170.0030.011
RAP (mmHg)0.5430.2640.764
Recto-anal pressure differential0.6190.0230.177
The rectal pressure during the push maneuver (mmHg)0.3110.0990.167
RAIR (mL)<0.010.4890.030
First sensation (mL)<0.01<0.010.015
Defecation threshold (mL)0.2650.0410.102
MRP/RAP0.0370.0390.034
Table 10. Manometric parameters in patients depending on the duration of diabetes.
Table 10. Manometric parameters in patients depending on the duration of diabetes.
VariablesDiabetes DurationU Manna-Whitney Test
<10 Years (N = 15)≥10 Years (N = 35)
XSDMMinMaxXSDMMinMaxp
MRP (mmHg)96.8522.7798.0049.00123.9079.7323.5282.9018.00122.700.024
MSP (mmHg)203.3179.82207.90104.90388.10148.4162.51151.2020.10299.700.026
HPZ (cm)3.650.833.702.004.803.520.763.701.604.600.603
Duration of sustained squeeze (s)13.915.7113.502.9020.1015.215.6218.202.5020.100.482
RAP (mmHg)81.7028.3580.3038.90124.9072.4927.5169.2023.40133.100.295
Recto-anal pressure differential−27.8138.01−22.70−99.4060.70−26.0526.33−23.00−74.4021.700.695
The rectal pressure during the push maneuver (mmHg)50.0329.3553.207.5096.4046.4325.5149.20−18.5090.900.767
RAIR (mL)47.3344.3140.000.00170.0043.4334.2140.000.00130.000.907
First sensation (mL)38.0015.2140.0020.0070.0050.8628.1140.0020.00140.000.120
Defecation threshold (mL)82.6740.9680.0030.00200.0087.1437.5470.0040.00200.000.691
Minimal compliance−0.351.460.28−4.880.400.001.930.29−11.100.670.058
Maximum compliance4.181.873.911.618.364.184.073.041.4425.600.305
MRP/RAP1.290.460.130.712.471.190.481.120.543.040.459
X—mean; SD—standard deviation. M—median Min—minimal. Max—maximal; p < 0.05.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Reszczyńska, M.; Kempiński, R. The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients. J. Clin. Med. 2021, 10, 415. https://doi.org/10.3390/jcm10030415

AMA Style

Reszczyńska M, Kempiński R. The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients. Journal of Clinical Medicine. 2021; 10(3):415. https://doi.org/10.3390/jcm10030415

Chicago/Turabian Style

Reszczyńska, Małgorzata, and Radosław Kempiński. 2021. "The Prevalence of Enteropathy Symptoms from the Lower Gastrointestinal Tract and the Evaluation of Anorectal Function in Diabetes Mellitus Patients" Journal of Clinical Medicine 10, no. 3: 415. https://doi.org/10.3390/jcm10030415

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop